PATENT CLAIM ANALYSIS

Application Number: 15949156
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["424", "142100"]

Abstract:
The disclosure relates to novel uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.

Claim (Index 16):
The method according to  claim 1 , wherein the antibody or antigen binding fragment thereof is administered to the patient for about 6 months.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 91.0
- Lexical Diversity: 1.46
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15304010', '15456392', '12767509', '15637867', '14447444']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7497266329930472
- 35 USC 102 Novelty (BERT): 0.5572449250478932
- Combined Prediction Score: 0.7304784621985317
- Mean Citation Score: 386.55955200000005
- Max Citation Score: 430.37146
- Similarity Product: 301.306370282929

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test